The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-01 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Troponin C binds to calcium ions (Ca2+) to produce a conformational change in TnI Troponin T binds to tropomyosin, interlocking them to form a troponin-tropomyosin complex with thin filaments Troponin I binds to actin in thin myofilaments to hold the actin-tropomyosin complex in place. It inhibits the ATPase activise of actomyosin. Inside the cardiac troponin complex, the strongest interaction between molecules is the cTnI–TnC binary complex, especially in the presence of Ca2+ (KA = 1.5 × 10−8 M−1). TnC, forming a complex with cTnI, changes the conformation of cTnI molecule and shields part of its surface. According to the latest data cTnI is released in the blood stream of the patient in the form of binary complex with TnC or ternary complex with cTnT and TnC. cTnI-TnC complex formation plays an important positive role in improving the stability of cTnI molecule. cTnI, which is extremely unstable in its free form, demonstrates significantly better stability in complex with TnC or in ternary cTnI-cTnT-TnC complex. It has been demonstrated that stability of cTnI in native complex is significantly better than stability of the purified form of the protein or the stability of cTnI in artificial troponin complexes combined from purified proteins.
He ruled that only Whitehall could determine what constituted the maintenance of "law and order" in Rhodesia, and that the Rhodesian emergency measures were unlawful as they had been formalised by the Officer Administering the Government, a post-UDI figure who was, in British eyes, unconstitutional. Reid concluded that Madzimbamuto was illegally detained. Harry Davies, one of the Rhodesian judges, announced on 8 August that the Rhodesian courts would not consider this ruling binding as they no longer accepted the Privy Council as part of the Rhodesian judicial hierarchy. Justice J. R. Dendy Young resigned in protest at Davies' ruling on 12 August and four days later was sworn in as Chief Justice of Botswana. The Rhodesian High Court granted full de jure recognition to the post-UDI government on 13 September 1968, while rejecting the appeals of 32 black Rhodesians who had been a month earlier convicted of terrorist offences and sentenced to death. Beadle declared that while he believed the Rhodesian judiciary should respect rulings of the Privy Council "so far as possible", the judgement of 23 July had made it legally impossible for Rhodesian judges to continue under the 1961 constitution. He asserted that the court therefore faced a choice between the 1965 constitution and a legal vacuum, the latter of which he felt he could not endorse.
== Location and classification == BAT's presence in adult humans was discovered in 2003 during FDG-PET scans to detect metastatic cancers. Using these scans and data from human autopsies, several deposits have been identified. In infants, brown adipose tissue deposits include: interscapular, supraclavicular, suprarenal, pericardial, para-aortic and around the pancreas, kidney and trachea. These deposits gradually get more white fat-like during adulthood. In adults, the deposits that are most often detected in FDG-PET scans are the supraclavicular, paravertebral, mediastinal, para-aortic and suprarenal ones. It remains to be determined whether these deposits are 'classical' brown adipose tissue or beige/brite fat.
Sources: en.wikipedia.org
The National Dope Testing Laboratory (NDTL) is a premier analytical testing & research organization established as an autonomous body under the Ministry of Youth Affairs and Sports, Government of India. It is the only laboratory in the country responsible for human sports dope testing. It is headed by Chief Executive Officer (CEO). Dr. Puran Lal Sahu is the Scientific Director of NDTL. It is accredited by National Accreditation Board for Testing & Calibration Laboratories, NABL (ISO/IEC 17025:2017) for human dope testing of urine & blood samples from human sports. NDTL is one of the 29 WADA accredited laboratories Archived 2021-04-18 at the Wayback Machine in the world. It is one of the modern and state-of-the-art laboratories in the country equipped with the latest analytical instrumentation.
=== The Lancet COVID-19 Commission task force === In November 2020, Richard Horton, editor of The Lancet, appointed economist Jeffrey Sachs as chair of its COVID-19 Commission, with wide-ranging goals relating to the virus and pandemic. Sachs set up a number of task forces, including one on the origins of the virus. Sachs appointed Peter Daszak, a colleague of Sachs' at Columbia, to head this task force, two weeks after the Trump administration prematurely ended a federal grant supporting a project led by Daszak, EcoHealth Alliance, which worked with the Wuhan Institute of Virology. This appointment was criticised as creating a conflict of interest, for instance by Richard Ebright, chemical biologist at Rutgers University, who called the commission an "entirely Potemkin commission" in the National Review. Daszak stated that the task force was formed to "conduct a thorough and rigorous investigation into the origins and early spread of SARS-CoV-2". The task force has twelve members with backgrounds in One Health, outbreak investigation, virology, lab biosecurity and disease ecology. The task force planned to analyse scientific findings and did not plan to visit China. However, as Sachs became increasingly drawn to the lab leak theory, he came into conflict with Daszak and his task force. In June 2021, The Lancet announced that Daszak had recused himself from the commission. On 25 September 2021, the task force work was folded after procedural concerns and a need to broaden its scope to examine transparency and government regulation of risky laboratory research.
For the next three years, DiCaprio narrated documentaries and served as a producer for films. In 2016, he was an executive producer for The Ivory Game and Catching the Sun; he also produced, hosted and narrated the documentary Before the Flood about climate change. He produced the crime drama Live by Night (2016), which received unenthusiastic reviews and failed to recoup its $65 million production budget. His next production ventures were in 2018—the psychological horror Delirium and the commercially failed action–adventure Robin Hood. After producing and narrating the 2019 global warming documentary Ice on Fire, DiCaprio returned to acting following a four-year break in Quentin Tarantino's comedy-drama Once Upon a Time in Hollywood, which traces the relationship between Rick Dalton (DiCaprio), an aging television actor and his stuntman, Cliff Booth (Brad Pitt). To help the film's financing, DiCaprio and Pitt agreed to take a pay cut, and they each received $10 million. DiCaprio liked working with Pitt, and Tarantino described the pair as the most exciting since Robert Redford and Paul Newman. DiCaprio was fascinated with the film's homage to Hollywood and focus on the friendship between his and Pitt's characters. He drew from real-life experience of witnessing the struggles and rejections of his actor friends in the industry. The film premiered at the 2019 Cannes Film Festival, where critics praised his and Pitt's performances.
Carpal tunnel syndrome (CTS) is the symptoms and signs characteristic of compressive median neuropathy at the carpal tunnel of the wrist. Compressive median neuropathy is a structural, largely hereditary condition that is usually measurable in both wrists. Most cases of median neuropathy at the carpal tunnel are idiopathic, meaning there is no known cause. Other causes of median nerve compression at the carpal tunnel include bleeding, swelling, and deformity associated with a wrist fracture. Carpal tunnel syndrome can also occur with rheumatoid arthritis, due to the enlarged synovial lining of the tendons causing median nerve compression. The main symptoms are numbness and tingling of the thumb, index finger, middle finger, and the thumb side of the ring finger, as well as pain in the hand and fingers. Symptoms are typically most troublesome at night. Many people sleep with their wrists bent, and the ensuing symptoms may lead to awakening. People wake less often at night if they wear a wrist splint. Untreated, and over years to decades, CTS causes loss of sensitivity, weakness, and shrinkage (atrophy) of the thenar muscles at the base of the thumb. Work-related factors such as vibration, wrist extension or flexion, hand force, and repetitive strain are risk factors for CTS. Other risk factors include being female, obesity, diabetes, rheumatoid arthritis, thyroid disease, and genetics. Diagnosis can be made with a high probability based on characteristic symptoms and signs. It can also be measured with electrodiagnostic tests.
Sources: en.wikipedia.org
== Advantages == Many protein-containing solutions have the highest absorption at 280 nm in the spectrophotometer, the UV range. This requires spectrophotometers capable of measuring in the UV range, which many cannot. Additionally, the absorption maxima at 280 nm requires that proteins contain aromatic amino acids such as tyrosine (Y), phenylalanine (F) and/or tryptophan (W). Not all proteins contain these amino acids, a fact which will skew the concentration measurements. If nucleic acids are present in the sample, they would also absorb light at 280 nm, skewing the results further. By using the Bradford protein assay, one can avoid all of these complications by simply mixing the protein samples with the Coomassie brilliant blue G-250 dye (Bradford reagent) and measuring their absorbances at 595 nm, which is in the visible range and may be accurately measured by the use of a mobile smartphone camera. The procedure for Bradford protein assay is very easy and simple to follow. It is done in one step where the Bradford reagent is added to a test tube along with the sample. After mixing well, the mixture almost immediately changes to a blue color. When the dye binds to the proteins through a process that takes about 2 minutes, a change in the absorption maximum of the dye from 465 nm to 595 nm in acidic solutions occurs.
Deficiency of VWF, therefore, shows primarily in organs with extensive small vessels, such as skin, gastrointestinal tract, and uterus. In angiodysplasia, a form of telangiectasia of the colon, shear stress is much higher than in average capillaries, and the risk of bleeding is increased concomitantly. In more severe cases of type 1 VWD, genetic changes are common within the VWF gene and are highly penetrant. In milder cases of type 1 VWD, a complex spectrum of molecular pathology may exist in addition to polymorphisms of the VWF gene alone. The individual's ABO blood group can influence presentation and pathology of VWD. Those individuals with blood group O have a lower mean level than individuals with other blood groups. Unless ABO group-specific VWF:antigen reference ranges are used, normal group O individuals can be diagnosed as type I VWD, and some individuals of blood group AB with a genetic defect of VWF may have the diagnosis overlooked because VWF levels are elevated due to blood group.
However, in later versions both teams have gained substantial advantage from the addition of a map hotkey. This overlays the whole level, showing teammates and friendly structures; plus enemies and structures currently in view of comrades, and areas under attack. The aliens start with one active hive, randomly chosen from the 3 hive spots of the map. Active hives heal damaged aliens and respawn dead players. Marines initially spawn in a set location on the map, and after that spawn from Infantry Portals, which can be built in a set radius of the Command Chair. Healing and ammunition can be dropped by the commander in 'packs' (at a cost) or obtained free from an Armoury. The teams compete for territory, and critically for the resources ('res') it offers. The currency for both sides, resources are obtained by building resource towers to tap the nozzles sited around the map. This is another area where the teams have a key difference - while marines draw on a common pool of resources, each alien accumulates a personal store. This further increases the requirement for teamwork on the alien side, to achieve the right balance of hives, lifeforms, resource towers and chambers. The game ends when either all the marines or aliens are dead, and have no means to respawn. For the Frontiersmen (marine) side, this entails destroying all alien hives, ensuring no further alien players may respawn, and then hunting the rest down.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.